Carvedilol: Preclinical profile and rationale for its use in hypertension, coronary syndromes, and congestive heart failure

Cardiovascular Reviews and Reports

Volumn 17, Issue 10, 1996, Pages 27-38

  Feuerstein, Giora Z ^a   Ruffolo Jr , Robert R ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; HYDROXYL RADICAL; OXYGEN RADICAL; PLACEBO; RADICAL;

ANTIOXIDANT ACTIVITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG MECHANISM; DRUG STRUCTURE; HEART MUSCLE ISCHEMIA; HEMODYNAMICS; HUMAN; HYPERTENSION; PROTECTION; REVIEW;

EID: 0029910667     PISSN: 01973118     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Sponer G, Bartsch W, Strein K, et al. The pharmacological profile of carvedilol as a ß-blocking agent with vasodilating and hypotensive properties. J Cardiovasc Pharmacol. 1987;9:315-327.
2. 1-adrenoceptors. Chirality. 1989;1:265-270.
3. Mollendorff EV, Sponer G, Strein K, et al. Carvedilol. In Scriabine A (ed). New Cardiovascular Drugs. New York: Raven Press; 1987:135-153.
4. Smith EF, Slivjak MJ, Gagnon R. Single and repeated doses of the vasodilator/ß-adrenergic antagonist, carvedilol, block cirazoline- and isoproterenol-mediated hemodynamic responses in the conscious rat. Cardiovasc Drugs Ther. 1992;6:499-504.
5. Feuerstein GZ, Poste G, Ruffolo RR Jr. Carvedilol update III: Rationale for use in congestive heart failure. Drugs Today. 1995;31:307-326.
6. Yue T-L, Cheng HY, Lysko PG, et al. Carvedilol, a new vasodilator and beta-adrenoceptor antagonist, is an antioxidant and free radical scavenger. Pharmacol Exp Ther. 1992;263:92-98.
7. Yue T-L, liu T, Feuerstein G. Carvedilol, a new vasodilator and ß-adrenoceptor antagonist, inhibits oxygen-radical-mediated lipid peroxidation in swine ventricular membranes. Pharmacol Commun. 1992;1:27-35.
8. Yue T-L, Lysko P, Barone FC, et al. Carvedilol a new antihypertensive drug with unique antioxidant activity: Potential role in cerebroprotection. NY Acad Sci. 1994;738:230-242.
9. McPhillips JJ, Schwemer GT, Scott DI, et al. Effects of carvedilol on blood pressure in patients with mild to moderate hypertension. Drugs. 1988;36(suppl 6):82-91.
10. Lopez BL, Christopher TA, Yue T-L, et al. Carvedilol, a new ß-adrenoceptor blocker antihypertensive drug, protects against free radical-induced endothelial dysfunction. Pharmacology. 1995;5:165-173.
11. Yue T-L, McKenna PJ, Lysko PG, et al. SB 211475, a metabolite of carvedilol, a novel antihypertensive agent, is a potent antioxidant. Eur J Pharmacol. 1994;251:237-243.
12. Feuerstein R, Yue T-L. A potent antioxidant, SB 209995, inhibits oxygen-radical-mediated lipid peroxidation and cytotoxicity. Pharmacology. 1994;48:385-391.
13. Nichols AJ, Gellai M, Ruffolo RR Jr. Studies on the mechanism of arterial vasodilation produced the novel antihypertensive agent, carvedilol. Fundam Clin Pharmacol. 1991;5:25-38.
14. Ruffolo RR Jr, Boyle DA, Venuti RP, et al. Carvedilol (Kredex®): A novel multiple action cardiovascular agent. Drugs Today. 1991;27:465-492.
15. Ruffolo RR Jr, Boyle DA, Brooks DP, et al. Carvedilol, a novel cardiovascular drug with multiple actions. Cardiovasc Drug Res. 1992;10:127-157.
16. Gellai M, DeWolf R, Ruffolo RR Jr. Effect of carvedilol on renal hemodynamics and renal excretory function in spontaneously hypertensive rats. Pharmacology. 1990;41:200-206.
17. Brooks DP, Short BG, Cyronak MJ, et al. Comparison between carvedilol and captopril in rats with partial ablation-induced chronic renal failure. Br J Pharmacol. 1993;109:581-586.
18. Albrightson CR, Zabko-Potapovich B, Brooks DP. Effect of carvedilol on mitogen-stimulated mesangial cell proliferation. Pharmacol Commun. 1992;1(4):267-272.
19. Greenberg BH. The medical management of chronic heart failure. In: Hosenpud JD, Greenberg BH (eds). Congestive Heart Failure: Pathophysiology, Diagnosis and Comprehensive Approach to Management. New York: Springer Verlag; 1994:628-644.
20. Hamburger SA, Barone FC, Feuerstein GZ, et al. Carvedilol (Kredex®) reduces infarct size in a canine model of acute myocardial infarction. Pharmacology. 1991;43:113-120.
21. Bril A, Slivjak M, DiMartino J, et al. Cardioprotective effects of carvedilol, a novel ß-adrenoceptor antagonist with vasodilating properties, in anaesthetised minipigs: Comparison with propranolol. Cardiovasc Res. 1992;26:518-525.
22. Feuerstein GZ, Hamburger SA, Smith EF, et al. Myocardial protection with carvedilol. Cardiovasc Pharmacol. 1992;19(suppl 1):S138-S141.
23. Feuerstein GZ, Ruffolo RR Jr. Comparison of the ability of two vasodilating ß-blockers, carvedilol and celiprolol, to reduce infarct size in a pig model of acute myocardial infarction. Pharmacol Commun. 1994;5(1):57-63.
24. Bril A, Tomasi V, Lavilie MP. Antiarrhythmic effects of carvedilol in rat isolated heart subjected to regional ischemia and reperfusion. Pharmacol Commun. 1995;5:291-300.
25. Ma X-L, Yue T-L, Lopez BL, et al. Carvedilol, a new ß-adrenoceptor blocker and free radical scavenger, attenuates myocardial ischemia-reperfusion injury in hypercholesterolemic rabbits. J Pharmacol Exp Ther. 1996;277:128-136.
26. Brunvand H, Froyland L, Hexeberg E, et al. Carvedilol improvces function and reduces infarct size in the feline myocardium by protecting against reperfusion injury. Eur J Pharmacol. In Press.
27. Owens GK, Rabinovitch PS, Schwartz SM. Smooth muscle cell hypertrophy versus hyperplasia in hypertension. Proc Natl Acad Sci USA. 1989;78:7759.
28. McMahon SW, Cutler JA, Furberg ED, et al. The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease. A review of randomized controlled trials. Prog Cardiovasc Dis. 1986;29(suppl):99-118.
29. Sung CP, Arleth AJ, Ohlstein EH. Carvedilol inhibits vascular smooth muscle cell proliferation. J Cardiovasc Pharmacol. 1993;21:221-227.
30. Yue T-L, Gu JL, Feuerstein G. Carvedilol, a new ß-adrenoceptor antagonist and vasodilator antihypertensive drug, inhibits oxygen radical mediated lipid peroxidadon in swine ventricular membranes. Pharmacol Commun. 1992;1:27-35.
31. Yue T-L, McKenna PJ, Ruffolo RR Jr, et al. Carvedilol, a new adrenoceptor antagonist and vasodilator antihypertensive drug, inhibits superoxide release from human neutrophils. Eur J Pharmacol. 1992;214:1669-1673.
32. Waagstein F, Hjalmarson A, Varnauskas E, et al. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J. 1975;37:1022-1036.
33. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349-1355.
34. McMurray J, Chopra M, Abdullah I, et al. Evidence of oxidative stress in chronic heart failure in humans. Eur Heart J. 1993;14:1493-1498.
35. Schreck R, Reiber P, Baeccerle PA. Reactive oxygen intermediates as apparently widely used second messengers in the activation of NF-kB transcription factor and HIV-1. EMBO J. 1991;10:2247-2258.
36. Schreck R, Meier B, Manuel D, et al. Dithiocarbamate as potent inhibitors of nuclear factor κB activation in intact cells. J Exp Med. 1992;175:1181-1194.
37. Schreck R, Baeuerle PA. A role for oxygen radicals as second messengers. Trends Cell Biol. 1991;1:39-44.
38. Collins T. Biology of disease: Endothelial nuclear factor-kB and the initiation of the atherosclerotic lesion. Lab Invest. 1993;68:499-508.
39. Schindler U, Baichwal VR. Three NF-κB binding sites in the human E-selectin gene required for maximal tumor necrosis factor alpha-induced expression. Mol Cell Biol. 1994;14:5820-5831.
40. 2 functions in an antioxidant pathway to prevent apoptosis. Cell. 1993;75:241-251.
41. Gottlieb RA, Burleson KO, Kloner RA, et al. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J. Clin Invest. 1994;94:1621-1628.
42. Entman ML, Michael L, Rosson RD, et al. Inflammation in the course of early myocardial ischemia. FASEB J. 1991;5:2529-2537.
43. Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323:236-241.
44. Podrid PJ, Fogel RI, Tordjman-Fuchs T. Arrhythmia in patients with a cardiomyopathy and congestive heart failure. In Hosenpud JD, Greenberg BH (eds). Congestive Heart Failure: Pathophysiology, Diagnosis and Comprehensive Approach to Management. New York: Springer-Verlag; 1994:645-686.
45. Barone FC, Nelson SH, Ohlstein EH, et al. Chronic carvedilol and propranolol reduces mortality and renal damage in hypertensive stroke-prone rats. J Pharmacol Exp Ther. In Press.